Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
A prototypical patient is presented to introduce important design issues for clinical trials of antibacterials in the treatment of community-acquired pneumonia.
Gilbert
David N
DN
Providence Portland Medical Center and Oregon Health and Sciences University, Portland, Oregon 97213, USA. david.gilbert@providence.org
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D008297:Male; D009177:Mycoplasma pneumoniae / Q000187:drug effects; D011014:Pneumonia / Q000188:drug therapy* / Q000209:etiology*; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy*; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy*; D012107:Research Design; D013296:Streptococcus pneumoniae / Q000187:drug effects; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents